Literature DB >> 15180656

Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.

Brent A Johnson1, Anastasios A Tsiatis.   

Abstract

After a treatment is found to be effective in a clinical study, attention often focuses on the effect of treatment duration on outcome. Such an analysis facilitates recommendations on the most beneficial treatment duration. In many studies, the treatment duration, within certain limits, is left to the discretion of the investigators. It is often the case that treatment must be terminated prematurely due to an adverse event, in which case a recommended treatment duration is part of a policy that treats patients for a specified length of time or until a treatment-censoring event occurs, whichever comes first. Evaluating mean response for a particular treatment-duration policy from observational data is difficult due to censoring and the fact that it may not be reasonable to assume patients are prognostically similar across all treatment strategies. We propose an estimator for mean response as a function of treatment-duration policy under these conditions. The method uses potential outcomes and embodies assumptions that allow consistent estimation of the mean response. The estimator is evaluated through simulation studies and demonstrated by application to the ESPRIT infusion trial coordinated at Duke University Medical Center.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180656     DOI: 10.1111/j.0006-341X.2004.00175.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.

Authors:  Connie N Hess; Phillip J Schulte; L Kristin Newby; Philippe Gabriel Steg; Anthony J Dalby; Marc J Schweiger; Basil S Lewis; Paul W Armstrong; Robert M Califf; Frans van de Werf; Robert A Harrington
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

2.  A Joint Modeling Approach for Right Censored High Dimensional Multivariate Longitudinal Data.

Authors:  Miran A Jaffa; Mulugeta Gebregziabher; Ayad A Jaffa
Journal:  J Biom Biostat       Date:  2014-08

3.  Direct estimation for adaptive treatment length policies: Methods and application to evaluating the effect of delayed PEG insertion.

Authors:  Xin Lu; Brent A Johnson
Journal:  Biometrics       Date:  2016-12-23       Impact factor: 2.571

4.  Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach.

Authors:  Shu Yang; Anastasios A Tsiatis; Michael Blazing
Journal:  Biometrics       Date:  2018-01-22       Impact factor: 2.571

5.  Nested g-computation: A causal approach to analysis of censored medical costs in the presence of time-varying treatment.

Authors:  Jason A Roy; Nandita Mitra; Andrew J Spieker; Emily M Ko
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2020-08-25       Impact factor: 1.864

6.  Treatment-competing events in dynamic regimes.

Authors:  Brent A Johnson
Journal:  Lifetime Data Anal       Date:  2008-06       Impact factor: 1.588

7.  Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.

Authors:  Brent A Johnson; Heather Ribaudo; Roy M Gulick; Joseph J Eron
Journal:  Biometrics       Date:  2013-07-17       Impact factor: 2.571

8.  Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection.

Authors:  Liangyuan Hu; Joseph W Hogan; Ann W Mwangi; Abraham Siika
Journal:  Biometrics       Date:  2017-09-28       Impact factor: 2.571

9.  Estimating mean potential outcome under adaptive treatment length strategies in continuous time.

Authors:  Hao Sun; Ashkan Ertefaie; Brent A Johnson
Journal:  Biometrics       Date:  2021-06-04       Impact factor: 1.701

10.  The effect of treatment delay on time-to-recovery in the presence of unobserved heterogeneity.

Authors:  Nan van Geloven; Theodor A Balan; Hein Putter; Saskia le Cessie
Journal:  Biom J       Date:  2020-01-20       Impact factor: 2.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.